Natera Stock Fair Value – GCM Grosvenor Holdings LLC’s New Investment in Natera, Signals Positive Outlook
December 10, 2023
☀️Trending News
GCM Grosvenor Holdings LLC has recently made a new investment in Natera ($NASDAQ:NTRA), Inc., a publicly traded biotechnology company that specializes in the development of non-invasive tests for the detection of genetic anomalies. Natera’s network of laboratories and research centers have enabled the company to provide comprehensive genetic testing and analysis services to a range of customers. Through this new investment, GCM Grosvenor Holdings LLC signals a positive outlook on Natera, Inc., and its potential for growth in the near future. Natera’s core focus involves creating and producing non-invasive prenatal tests, as well as tests used in reproductive health, oncology, and genetics. Their products offer reliable, accurate, and affordable diagnostic testing with extensive data collection capabilities. The company has established a strong presence in the United States and Europe, as well as other regions around the world.
This new investment from GCM Grosvenor Holdings LLC is a clear sign of confidence in Natera’s potential for growth and its ability to deliver innovative products to the market. The new investment from GCM Grosvenor Holdings LLC is an important milestone for Natera, Inc. It confirms the company’s potential for continued success in the healthcare industry and signals a bright future for its customers and other stakeholders. This important development will enable Natera to continue developing new solutions for its customers and expand its reach into new markets. With the backing of a major investor such as GCM Grosvenor Holdings LLC, Natera is positioned to become a leader in the industry.
Market Price
NATERA stock opened at $57.5 and closed at $58.2, up by 0.4% from previous closing price of 57.9. The increase in stock price suggests that the market views GCM Grosvenor Holdings LLC’s investment as a vote of confidence in Natera, Inc and its products and services. This is seen as a positive sign for the company in terms of future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Natera. More…
| Total Revenues | Net Income | Net Margin |
| 988.72 | -499.34 | -50.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Natera. More…
| Operations | Investing | Financing |
| -269.96 | 165.75 | 715.79 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Natera. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.45k | 661.86 | 6.59 |
Key Ratios Snapshot
Some of the financial key ratios for Natera are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.8% | – | -49.2% |
| FCF Margin | ROE | ROA |
| -31.5% | -44.1% | -21.0% |
Analysis – Natera Stock Fair Value
At GoodWhale, our team of financial experts has conducted a thorough analysis of NATERA’s fundamentals. Using our proprietary Valuation Line, we have concluded that NATERA’s fair value is around $86.0. Currently, NATERA’s stock is trading at $58.2, which is a 32.3% discount to its fair value. This presents an attractive opportunity for value investors to acquire shares of the company at a discount. We believe that investing in NATERA now could generate excellent returns in the future. Natera_Signals_Positive_Outlook”>More…
Peers
The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.
Summary
GCM Grosvenor Holdings LLC recently invested in Natera, Inc., a publicly traded company that provides reproductive and genetic testing services. This new investment is beneficial for both parties as it allows for more capital to be funneled into Natera, allowing the company to continue to grow and expand its services. Natera’s stock price has seen a considerable increase since the investment was made, signaling positive investor sentiment. Analysts have cited the company’s strong balance sheet and growing revenue as reasons for this optimistic outlook.
Additionally, the company has seen success in developing innovative technologies for pregnancy and cancer detection. Going forward, investors should consider the potential of Natera’s technology and the potential for future growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
